ALLO profile · all as-reported value updates

Allogene Therapeutics, Inc. (ALLO) as-reported value updates

Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.

Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.

Rows publish only when the later filed value differs by at least 1.0% and at least $1,000,000, after dropping differences that match under the capped trailing-zero precision rule. The delta percent is delta divided by the larger absolute filed value. Values are annual standardized facts only; metrics whose differences fall below those thresholds or match the capped precision rule are not published as rows.

Ledger table figure

Metric	FY	Earliest XBRL-filed value	Currently on file	Difference	Difference %	Label	Filing links	Notes
Operating income OperatingIncomeLoss	2021	-255,792,000 filed 2022-02-23 · 10-K	-180,192,000 filed 2024-03-14 · 10-K	75,600,000	+29.56%	figure amended in 10-K/A	0001737287-22-000013 0001737287-24-000021	4 filed observations examined for this concept and period.
Net income NetIncomeLoss	2021	-257,005,000 filed 2022-02-23 · 10-K	-182,051,000 filed 2024-03-14 · 10-K	74,954,000	+29.16%	figure amended in 10-K/A	0001737287-22-000013 0001737287-24-000021	4 filed observations examined for this concept and period.
Net income NetIncomeLoss	2020	-250,221,000 filed 2021-02-25 · 10-K	-316,381,000 filed 2024-03-14 · 10-K/A	-66,160,000	-20.91%	figure amended in 10-K/A	0001737287-21-000009 0001737287-24-000018	4 filed observations examined for this concept and period.
Stockholders' equity StockholdersEquity	2020	1,079,617,000 filed 2021-02-25 · 10-K	1,013,457,000 filed 2024-03-14 · 10-K	-66,160,000	-6.13%	figure amended in 10-K/A	0001737287-21-000009 0001737287-24-000021	5 filed observations examined for this concept and period.
Liabilities Liabilities	2021	122,228,000 filed 2022-02-23 · 10-K	125,628,000 filed 2024-03-14 · 10-K/A	3,400,000	+2.71%	figure amended in 10-K/A	0001737287-22-000013 0001737287-24-000018	3 filed observations examined for this concept and period.
Net income NetIncomeLoss	2022	-332,632,000 filed 2023-02-28 · 10-K	-340,414,000 filed 2024-03-14 · 10-K	-7,782,000	-2.29%	figure amended in 10-K/A	0001737287-23-000018 0001737287-24-000021	3 filed observations examined for this concept and period.
Liabilities Liabilities	2022	151,209,000 filed 2023-02-28 · 10-K	154,697,000 filed 2024-03-14 · 10-K	3,488,000	+2.25%	figure amended in 10-K/A	0001737287-23-000018 0001737287-24-000021	3 filed observations examined for this concept and period.
Assets Assets	2021	1,038,634,000 filed 2022-02-23 · 10-K	1,050,828,000 filed 2024-03-14 · 10-K/A	12,194,000	+1.16%	figure amended in 10-K/A	0001737287-22-000013 0001737287-24-000018	3 filed observations examined for this concept and period.